A Phase 1 safety study of GRNOPC1 in patients with neurologically complete, subacute, spinal cord injury
Phase of Trial: Phase I
Latest Information Update: 21 Mar 2017
At a glance
- Drugs OPC 1 (Primary)
- Indications Spinal cord injuries
- Focus Adverse reactions; First in man
- Sponsors Asterias Biotherapeutics
- 21 Mar 2017 Results published in an Asterias Biotherapeutics media release.
- 21 Jun 2016 According to an Asterias Biotherapeutics media release, the results of this trial will be presented at the 2016 International Society for Stem Cell Research (ISSCR) Annual Meeting.
- 24 May 2016 Positive long-term follow-up results published in Asterias Biotherapeutics media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History